Loading...
Loading...
Also known as: Prolia, denosumab injection
A monoclonal antibody biologic used for the treatment of osteoporosis in postmenopausal women at high risk of fracture, and for those who cannot tolerate bisphosphonates. Administered as a subcutaneous injection every six months by a healthcare professional.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Total Reports
7
Median Score (Wk 8)
6/10
Would Continue
57%
Avg Duration
11 wk
Most Common Goal
menopause
Most Reported Side Effect
Injection site reaction (29%)
Based on self-reported community data. Scores use a 1–10 scale.
Regulatory status does not mean an approach is safe or unsafe. Laws vary by country — check your local regulations.
Women who reported on Denosumab mentioned using it for the following goals. This does not mean it is intended for or achieves any of these outcomes.
Aggregated patterns from 7 self-reported experiences with Denosumab.
57% of women said they would continue this protocol
5.4/10 average self-reported outcome score at week 8
Most commonly reported effects: Injection site reaction, Fatigue, Back pain
Outcome Score Distribution (Week 8)
7 of 7 reports included a week 8 score
Would Continue Protocol
7 of 7 reports included this response
Commonly Reported Effects
Percentage of reports mentioning each effect
Based on 7 self-reported experiences. This is community data, not clinical evidence. Individual outcomes vary. Discuss any intervention with your healthcare provider.
7 reports from women who tried Denosumab
Denosumab wasn't for me. After 12 weeks of trying, my bone density concerns were much the same. I've stopped taking it.
I've been using Denosumab for about 12 weeks now for bone density concerns. the worst of the symptoms eased around week 3. I was sleeping through the night. I'd recommend discussing it with your GP.
I tried Denosumab for vaginal dryness and discomfort but the results were mixed. I noticed a subtle improvement, but the side effects made it hard to continue. I may try increasing the dose.
After 8 weeks on Denosumab, I'd say it made a modest difference to my joint pain and stiffness. Some symptoms improved while others stayed the same. Not a miracle but not nothing either.
Denosumab helped somewhat with my sleep problems and fatigue — hot flashes reduced a bit, though the brain fog lingered. Might try something different.
Research context compiled from published sources
Binds to RANKL (receptor activator of nuclear factor kappa-B ligand), preventing it from activating RANK on osteoclast precursors. This inhibits osteoclast formation, function, and survival, markedly reducing bone resorption. Results in significant increases in bone mineral density at all skeletal sites.
Well Studied
Extensive human research over many years, including randomized controlled trials.
Well Characterized
Decades of long-term safety data available from human use.
Dose ranges from published research. Individual dosing should be determined with your healthcare provider based on your specific circumstances.
Factual research context from published sources — not a safety assessment or recommendation. Research classifications may change as new data emerges.
Other approaches tracked on Narrated.
Data last updated: March 27, 2026